JLE

European Journal of Dermatology

MENU

Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab Volume 27, numéro 2, March-April 2017

Tableaux

Auteurs
1 Unit of Dermatology, University of Padua, Padua, Italy
2 Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Immune checkpoint inhibitors are monoclonal antibodies (mAb) belonging to different categories, namely those that block cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death 1 (PD1) expressed on T-cells, or programmed-death ligand 1 (PD-L1) expressed on tumour and antigen-presenting cells [1]. Although they have different functions, the common final effect of this class of drugs is the enhancement of the immune response against cancer cells [1]. One of the major PD-L1 inhibitors [...]